Business Wire

MN-NCIPHER-SECURITY

7.4.2020 09:12:10 CEST | Business Wire | Press release

Share
Customer Personal Information Is the Number One Data Protection Priority – nCipher 2020 Global Encryption Trends Study

As organizations accelerate digital initiatives such as cloud and the internet of things (IoT), and data volumes and types continue to rise, IT professionals cite protection of customer personal information as their number one priority, according to the 2020 Global Encryption Trends Study from the Ponemon Institute.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200407005297/en/

The Ponemon Institute has collaborated with nCipher Security , an Entrust Datacard company and world leader in hardware security modules (HSMs), on this multinational survey of how and why organizations deploy encryption, now in its fifteenth year.

Threats, drivers and priorities

For the first time, protecting consumer personal information is the top driver for deploying encryption (54% of respondents), outranking compliance, which ranked fourth (47%). Traditionally compliance with regulations was the top driver for deploying encryption, but has dropped in priority since 2017, indicating that encryption is transitioning from a requirement to a proactive choice to safeguard critical information.

Employee mistakes continue to be the biggest threat to sensitive data (54%) and significantly outweigh concerns over attacks by hackers (29%), or malicious insiders (20%). In contrast, the least significant threats cited include government eavesdropping (11%) and lawful data requests (12%).

Data discovery the number one challenge

With the proliferation of data from digital initiatives, cloud use, mobility, IoT devices and the advent of 5G networks, data discovery continues to be the biggest challenge in planning and executing a data encryption strategy, with 67% of respondents citing this as their top concern. And that is likely to increase, with a pandemic-driven surge in employees working remotely, using data at home, creating extra copies on personal devices and cloud storage.

Blockchain, quantum and adoption of new encryption technologies

The study indicates that 48% of organizations have adopted encryption strategies across their enterprises, up from 45% in 2019. With encryption deployment steadily growing, how are organizations looking ahead? In the near term, 60% of organizations plan to use blockchain, with cryptocurrency/wallets, asset transactions, identity, supply chain and smart contracts cited at the top use cases.

Other much-hyped technologies are not on IT organizations’ near-term radar. Most IT professionals see the mainstream adoption of multi-party computation at least five years away, with mainstream adoption of homomorphic encryption more than six years away, and quantum resistant algorithms over eight years out.

Trust, integrity, control

The use of hardware security modules (HSMs) continues to grow, with 48% of respondents deploying HSMs to provide a hardened, tamper-resistant environment with higher levels of trust, integrity and control for both data and applications. Organizations in Germany, the United States and Middle East are more likely to deploy HSMs, with Australia, Germany and the United States most likely to assign importance to HSMs as part of their organization’s encryption or key management activities.

HSM usage is no longer limited to traditional use cases such as public key infrastructure (PKI), databases, application and network encryption (TLS/SSL). The demand for trusted encryption for new digital initiatives has driven significant HSM growth for big data encryption (up 17%) code signing (up 12%), IoT root of trust (up 10%) and document signing (up 7%). Additionally, 35% of respondents report using HSMs to secure access to public cloud applications.

The race to the cloud

Eighty-three percent of respondents report transferring sensitive data to the cloud, or planning to do so within the next 12 to 24 months, with organizations in the United States, Brazil, Germany, India and South Korea doing so most frequently.

In the next 12 months, respondents predict a significant increase in the ownership and operation of HSMs to generate and manage Bring Your Own Key (BYOK), and integration with a Cloud Access Security Broker (CASB) to manage keys and cryptographic operations. The survey found that the most important cloud encryption features are:

  • support for Key Management Interoperability Protocol (KMIP) (67%)
  • security information and event management (SIEM) integration (62%)
  • granular access controls (60%)
  • key usage audit logs (55%), and
  • privileged user access controls (50%).

“Consumers expect brands to keep their data safe from breaches and have their best interests at heart. The survey found that IT leaders are taking this seriously, with protection of consumer data cited as the top driver of encryption growth for the first time,” says Dr Larry Ponemon, chairman and founder of Ponemon Institute. “Encryption use is at an all-time high with 48% of respondents this year saying their organization has an overall encryption plan applied consistently across the entire enterprise, and a further 39% having a limited plan or strategy applied to certain application and data types.”

“As the world goes digital, the impact of the global pandemic highlights how security and identity have become critical for organizations and individuals both at work and at home,” says John Grimm vice president of strategy at nCipher Security. “Organizations are under relentless pressure to deliver high security and seamless access – protecting their customer data, business critical information and applications while ensuring business continuity. nCipher empowers customers by providing a high assurance security foundation that ensures the integrity and trustworthiness of their data, applications and intellectual property.”

Other key trends include:

  • The highest prevalence of organizations with an enterprise encryption strategy is in Germany (66%) followed by the United States (66%), Sweden (62%), Hong Kong (60%), Netherlands (56%) and the United Kingdom (54%).
  • Payment-related data (54% of respondents) and financial records (54% of respondents) are most likely to be encrypted.
  • The least likely data type to be encrypted is health-related information (25% of respondents), a surprising result given the sensitivity of this information and recent high-profile healthcare data breaches.
  • The industries seeing the most significant increase in extensive encryption usage are manufacturing (49%), hospitality (44%) and consumer products (43%).

Download the 2020 Global Encryption Trends Study here .

2020 Global Encryption Trends Study methodology

The 2020 Global Encryption Trends Study, based on research by the Ponemon Institute, captures how organizations around the world are dealing with compliance, increased threats, and the implementation of encryption to protect their business critical information and applications. 6,457 IT professionals were surveyed across multiple industry sectors in 17 countries/regions: Australia, Brazil, France, Germany, India, Japan, Hong Kong, Mexico, the Middle East (which is a combination of respondents located in Saudi Arabia and the United Arab Emirates), the Russian Federation, Southeast Asia (Indonesia, Malaysia, Philippines, Thailand, and Vietnam), South Korea, Taiwan, the United Kingdom, the United States and two new regions for the first time, Netherlands and Sweden.

About nCipher Security

nCipher Security, an Entrust Datacard company, is a leader in the general-purpose hardware security module (HSM) market, empowering world-leading organizations by delivering trust, integrity and control to their business-critical information and applications. Today’s fast-moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency – it also multiplies the security risks. Our cryptographic solutions secure emerging technologies such as cloud, IoT, blockchain, and digital payments and help meet new compliance mandates. We do this using our same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business-critical applications, ensure the integrity of your data and put you in complete control – today, tomorrow, always. www.ncipher.com

Follow us on LinkedIn , Twitter , Facebook and Instagram – search nCipherSecurity.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye